Bullish & Foolish
Full CLPT fundamentals All 466 on the Survival Watch

CLPTClearPoint Neuro, Inc.

Is ClearPoint Neuro struggling financially?

Yes, by its own account. ClearPoint Neuro told the SEC on 17 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$469.5M
Source filing
10-K 17 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

  • 12months

    If the burn speeds up

    Empty by Jun 2027

  • 17months

    If it eases off

    Empty by Nov 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$29.4M

÷

Cash burned over the last 12 months

$24.4M

What ClearPoint Neuro told the SEC

…as they become due, or fully execute our integration or growth strategies. An inability to raise a sufficient amount of additional capital would create substantial doubt about our ability to continue as a going concern. The funding requirements for our business will depend on many factors, including: the timing of broader market acceptance and adoption of our ClearPoint platform and IRRA flow…

ClearPoint Neuro, Inc., Form 10-K, filed 17 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.

Other Biotech/Pharma companies that filed the doubt